Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

ICON selected by BARDA to conduct anthrax vaccine clinical trial: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON selected by BARDA to conduct anthrax vaccine clinical trial


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it has been selected by the US Biomedical Advanced Research and Development

Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Premier, Inc. to Report Fiscal 2023 First-Quarter Results and Host Conference Call on November 1, 2022: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2023 First-Quarter Results and Host Conference Call on November 1, 2022


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 first quarter on Tuesday, November 1, 2022, at approximately 6:30 a.m. ET. The company will

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria
Novocure to Report Third Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Report Third Quarter 2022 Financial Results


Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open. Novocure management

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Convatec Group PLC: Director/ PDMR Shareholding
Convatec Group PLC: Director/ PDMR Shareholding
Convatec Group PLC: Director/ PDMR Shareholding
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Tavneos® erhält Swissmedic-Zulassung für die Behandlung ANCA-assoziierter Vaskulitis: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Tavneos® erhält Swissmedic-Zulassung für die Behandlung ANCA-assoziierter Vaskulitis


Vifor Fresenius Medical Care Renal Pharma (VFMCRP) hat heute die Zulassung von Tavneos® durch die Schweizerische Zulassungs- und Aufsichtsbehörde für Arzneimittel und Medizinprodukte Swissmedic

ICON plc Schedules Third Quarter 2022 Earnings Conference Call: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON plc Schedules Third Quarter 2022 Earnings Conference Call


ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the third quarter 2022 after the

Convatec Group PLC: Scrip Dividend - Total Issued Shares
Convatec Group PLC: Scrip Dividend - Total Issued Shares
Convatec Group PLC: Scrip Dividend - Total Issued Shares
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Convatec Group PLC: Results of 2022 AGM – Update Statement
Convatec Group PLC: Results of 2022 AGM – Update Statement
Convatec Group PLC: Results of 2022 AGM – Update Statement
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
LivaNova to Announce Third-Quarter 2022 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Announce Third-Quarter 2022 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third-quarter 2022 results on Wednesday, November 2, 2022, at 12

Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business


Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc